ArticleNature communications2023
Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Indirect protection and long-term effectiveness of inactivated COVID-19 vaccine: a stepped-wedge randomised trial in Serrana, Brazil.Scientific reports · 2026Trial
- Article
- Effectiveness of Inactivated COVID-19 Vaccination Against COVID-19-Related Hospitalization and Severe Outcomes in Adults ≥80 Years During Omicron Circulation in Beijing, China: Retrospective Cohort Study.JMIR public health and surveillance · 2026Article
- Long-term effectiveness of COVID-19 vaccination in preventing hospitalization among household contacts: A case-control study from December 2021 to April 2023.Human vaccines & immunotherapeutics · 2025Article
- Impact of unequal testing on vaccine effectiveness estimates across two study designs: a simulation study.Nature communications · 2025Article
- Effectiveness of inactivated COVID-19 vaccine against symptom severity in hospitalized COVID-19 patients infected with the Omicron variant.Archives of virology · 2025Article
- Protection afforded by post-infection SARS-CoV-2 vaccine doses: A cohort study in Shanghai.eLife · 2025Article
- Intelligent rehabilitation in an aging population: empowering human-machine interaction for hand function rehabilitation through 3D deep learning and point cloud.Frontiers in computational neuroscience · 2025Article
- Intensive Care Nurses' Perceptions, Knowledge, and Attitudes Toward Pressure Injury Prevention in Prone Position Patients: A Multicenter Cross-Sectional Study in Shanghai, China.Risk management and healthcare policy · 2025Article
- The Impact of Vaccination on COVID-19 Outcomes in Vietnam.Diagnostics (Basel, Switzerland) · 2024Article
- Safety, tolerability, and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine in healthy adults: an open-label randomized phase I clinical trial.Clinical and experimental vaccine research · 2024Article
- The effectiveness of COVID-19 vaccination in preventing hospitalisation and mortality: A nationwide cross-sectional study in Iran.Journal of global health · 2024Article
- Article
- The COVID-19 Vaccines Evaluation Program: Implementation, Management, and Experiences, 2021-2023.China CDC weekly · 2024Article
- Drug repositioning identifies salvinorin A and deacetylgedunin (DCG) enriched plant extracts as novel inhibitors of Mpro, RBD-ACE2 and TMPRRS2 proteins.RSC advances · 2024Article
- Article
- Prevalence, outcomes and associated factors of SARS-CoV-2 infection in psoriasis patients of Southwest China: a cross-sectional survey.Scientific reports · 2024Article
- Vaccines reduced hospital length of stay and fraction of inspired oxygen of COVID-19 patients: A retrospective cohort study.Preventive medicine reports · 2024Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted a matched retrospective cohort study of two cohorts to estimate inactivated vaccine effectiveness (VE) and its comparative effectiveness of booster dose among older people in Shanghai. Cohort 1 consisted of a vaccinated group (≥1 dose) and an unvaccinated group (3,317,475 pairs), and cohort 2 consisted of a booster vaccinated group and a fully vaccinated group (2,084,721 pairs). The Kaplan-Meier method and Cox regression models were used to estimate risk and hazard ratios (HRs) study outcomes. For cohort 1, the overall estimated VEs of ≥1 dose of inactivated vaccine against SARS-CoV-2 infection, severe/critical Covid-19, and Covid-19 related death were 24.7% (95%CI 23.7%-25.7%), 86.6% (83.1%-89.4%), and 93.2% (88.0%-96.1%), respectively. Subset analysis showed that the booster vaccination provided greatest protection. For cohort 2, compared with full vaccination, relative VEs of booster dose against corresponding outcome were 16.3% (14.4%-17.9%), 60.5% (37.8%-74.9%), and 81.7% (17.5%-95.9%). Here we show, although under the scenario of persistent dynamic zero-Covid policy and non-pharmaceutical interventions, promoting high uptake of the full vaccination series and booster dose among older adults is critically important. Timely vaccination with the booster dose provided effective protection against Covid-19 outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.